Orca Bio

We look forward to joining the global transplant community at the 52nd Annual Meeting of @TheEBMT in Madrid, where Orca Bio will present clinical data highlighting our investigational high-precision cell therapy programs. Read more about our #EBMT26 presentations: lnkd.in/gMaztxMi #hematology #oncology #celltherapy #bloodcancer #BMT

This month’s #EmployeeSpotlight is Mike Hirschmann, recently promoted to Orca Bio’s Chief Commercial Officer (CCO). Mike, previously our Senior Vice President of US Commercial, joined Orca Bio from Legend Biotech and brings nearly 30 years of biotechnology and pharmaceutical expertise, with specialization in hematology/oncology and cell gene therapy. His experience launching a landmark CAR-T therapy will be invaluable at #TeamOrcaBio as we look to bring a first-of-its-kind high-precision therapy to blood cancer patients. With the potential approval of our lead investigational cell therapy on the horizon, we’re thrilled to have Mike's experience and passion at the forefront of our commercial launch readiness efforts.

We are pleased to present new data at the 2026 Tandem Meetings of @ASTCT and @CIBMTR that support the potential of our investigational high-precision cell therapy in hematologic malignancies. Read the press release for details on our data and presentations: bit.ly/4tdLmHb #Tandem26 #Oncology #Hematology #CellTherapy

A blood cancer diagnosis can turn life upside down – for patients and the people who love them. On #WorldCancerDay, we’re united in support of the blood cancer community and committed to our mission of transforming the lives of patients through high-precision cell therapies.  For information and resources for patients, caregivers and providers, visit @BloodCancerUtd: bloodcancerunited.org #UnitedByUnique #BloodCancer

Attending the 2026 Tandem Meetings of @ASTCT and @CIBMTR next week in Salt Lake City? We’d love to connect at Booth #101. Learn more about our presentations highlighting new data and meaningful findings across our pipeline of investigational allogeneic T-cell immunotherapies for the treatment of multiple hematological malignancies: ow.ly/M6BO50Y59x7 #Tandem26 #hematology #oncology #cancerresearch #celltherapy

Orca Bio looks forward to joining the transplant community at the 2026 Tandem Meetings of the @ASTCT and @CIBMTR where we will present new clinical data on our investigational high-precision cell therapies. Read more about our nine #Tandem26 presentations in our press release: bit.ly/45lhcYk #hematology #oncology #celltherapy #bloodcancer #cancerresearch

This week, Orca Bio's CFO and Head of Strategy, Josh Murray, will join industry leaders and investors on a Fierce JPM Panel to discuss how biotech companies are navigating today’s funding environment, evaluating public versus private pathways and positioning for long-term growth as market conditions evolve. Looking forward to an insightful discussion! To register, visit: fiercejpmweek.com #Biotech #FierceJPMWeek #FierceJPM2026

Today, Orca Bio announced $250M in aggregate financing to support launch readiness preparations in addition to new clinical program advancements. Read more in our press release: bit.ly/4syGhcd #hematology #oncology #celltherapy

Next week, Orca Bio’s co-founder and CEO, Nathaniel Fernhoff, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. We look forward to engaging with the #biotech investor community and other industry leaders to highlight recent progress and preview anticipated milestones for the year ahead. More details on our presentation on Jan. 12 at 7:30 AM PT: bit.ly/44Yj1KF #JPM26 #bloodcancer #oncology #hematology #celltherapy

As we close out one of the most pivotal years in Orca Bio’s history, we’re proud of the momentum we’ve built across the organization. We look forward to carrying this energy into the new year, staying focused on our mission and the patients who inspire us every day. Together, we can make 2026 a year that truly changes lives. #celltherapy #hematology #oncology #patientsfirst

We are pleased to announce the pivotal Precision-T Phase 3 study results evaluating Orca-T, our lead investigational allogeneic T-cell immunotherapy, have been published in @ASH_hematology's peer-reviewed journal, Blood. Read more in our press release: bit.ly/4pE5KPu #bloodcancer #oncology #hematology #celltherapy

Another inspiring #ASH25 has come to a close! This year, we saw advances that push the boundaries of what’s possible for patients – more precise therapies, improved safety profiles and new insights that are shaping the future of care. It’s a powerful reminder that the scientific community is collectively raising the bar, and that the work we’re doing at Orca Bio is part of a broader shift toward more innovative, patient-centered treatment options. At Orca Bio, we are grateful for the collaboration, the science and the momentum driving this field forward. #celltherapy #hematology #oncology

We announced exciting new clinical data from our pipeline of investigational high-precision cell therapies at the 67th @ASH_hematology Annual Meeting, highlighting the latest results with Orca-T, Orca-Q and our OrCAR-T combination therapy. Read more in our press releases: ➡️ Orca-T: bit.ly/3YcZ92r ➡️ Orca-Q / OrCAR-T: bit.ly/4pypILO #ASH25 #bloodcancer #oncology #hematology #celltherapy

#TeamOrcaBio is looking forward to joining the hematology community in Orlando for #ASH25! Be sure to visit us at booth #1011 to learn about new data on our investigational allogeneic T-cell immunotherapies across hematological malignancies including AML, MDS and ALL. To learn more: bit.ly/4iB6KRJ #celltherapy #hematology #oncology #AML

At #TeamOrcaBio, we are grateful for the dedication of our incredible team, clinical trial partners, patients and their families, and the shared mission that ties us together: transforming the lives of people through high-precision cell therapy. This Thanksgiving, we wish you and your loved ones a joyful holiday. #bloodcancer #oncology #hematology

We’re thrilled to share that Orca-T has won the Fierce Life Sciences Innovation Award for Biotech Innovation of the year! This recognition highlights the breakthrough potential of Orca-T, our lead investigational allogeneic T-cell immunotherapy, and the dedication of the teams who are pushing the boundaries of what’s possible for patients. It’s an honor to be recognized among so many organizations working to move science forward. Thank you to @LifeSciEvents for this recognition, and to everyone at Orca Bio, our partners and supporters, who work tirelessly to further this mission every day. Read more here: bit.ly/4p8bFfL #FierceLifeSciencesAwards #FierceInnovationAwards

We’re excited to share that Lauren Smith, Orca Bio’s Chief Quality Officer, will speak on the Women in Leadership panel at the 9th Annual American Pharma Manufacturing and Outsourcing Summit. She’ll join industry peers to discuss navigating career challenges, mentoring future leaders, and the importance of building strong networks in shaping impactful careers. To learn more: bit.ly/4p8j65U #biotechleadership #hematology #oncology #celltherapy

November is #NationalMarrowAwarenessMonth – a time to celebrate the donors who make life-saving treatments possible, and the patients, families and care teams whose courage and support inspires our work. You can make a difference, too. By joining donor registries like @nmdp_org, @GiftofLife and @DKMS_us, you could be the match that gives someone a second chance at life. #hematology #bloodcancer #oncology

We are pleased to announce that Orca Bio will present new clinical data on our investigational high-precision cell therapies at the 67th @ASH_hematology Annual Meeting in Orlando, FL. More on our six #ASH25 presentations can be found here: bit.ly/47oB7qI #bloodcancer #oncology #hematology #celltherapy #AML